Stephanie Richards

Stephanie Richards is a partner in Goodwin’s nationally recognized Life Sciences group, counseling public and private companies at all stages of maturity as well as venture capital firms and investment banks across the life sciences industry. 

Stephanie advises clients on startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, mergers and acquisitions, and other complex transactions. She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance, capital raising and corporate governance matters. She joined Goodwin in 2018.

Stephanie’s recent client representations include the following:

Capital Markets

• SpringWorks Therapeutics in its $225 million PIPE financing
• Kymera Therapeutics in its $150 million PIPE financing
• Flagship Pioneering in its investment in a PIPE financing by Syros Pharmaceuticals
• Aura Biosciences in its $75.6 million initial public offering and its $75 million “at-the-market” offering 
• Ikena Oncology in its $133.6 million initial public offering and in its $100 million “at-the-market” offering
• Olink Holding AB (publ) in its $264 million initial public offering and $232.5 million secondary public offering
• iTeos Therapeutics in its $201 million initial public offering
• The underwriters in Freeline Therapeutics Holdings plc’s $159 million initial public offering
• Xeris Pharmaceuticals in its $85.5 million initial public offering, subsequent debt and equity follow on offerings and acquisition of Strongbridge Biopharma plc
• TCR² Therapeutics in its $75 million initial public offering and subsequent equity follow on offerings

Venture Capital Financings

• Repertoire Immune Medicines in its $189 million Series B financing
• Aura Biosciences in its $80 million Series E financing
• Ikena Oncology in its $120 million Series B financing
• Faze Medicines in its $81 million Series A financing
• Thrive Earlier Detection Corp. in its $110 million Series A financing and $257 million Series B financing
• iTeos Therapeutics in its $125 million Series B financing
• Third Rock Ventures in connection with their portfolio investments and related matters

Mergers and Acquisitions

• Inzen Therapeutics in its merger with Cygnal Therapeutics
• Valo Health in its announced 2021 deSPAC business combination with Khosla Ventures Acquisition Co. ($2.8 billion)
• Cogen Immune Medicines in its merger with Torque Therapeutics
• ProKidney and its lead investor, Pablo Legorreta, founder and CEO of Royalty Pharma, in the acquisition of inRegen and Twin City Bio, LLC
• Adhaere Pharmaceuticals in its sale to Gossamer Bio